Business Context and Reporting Period
Company: Innate Pharma S.A.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Date: April 28, 2025
Principal Executive Office: Marseille, France
Context: This filing serves as a cover document for a press release dated April 28, 2025 (Exhibit 99.1). The text provided contains only the cover page and signature block; the content of the press release is not included in the source text.
Key Financial Metrics
The provided filing text does not contain specific financial data. Consequently, the following metrics are not available in this document:
- Revenue: Not provided.
- Profit/Loss: Not provided.
- Cash Flow: Not provided.
- Margins: Not provided.
- Debt and Liquidity: Not provided.
Material Changes
The filing text does not provide comparative financial data or details regarding material changes versus prior periods. The specific nature of the update referenced in the attached press release is not described in the cover document.
Guidance, Outlook, and Risks
The source text does not include management commentary, forward-looking guidance, risk factors, contingencies, or descriptions of unusual items. These details would be contained within the referenced press release (Exhibit 99.1), which is not part of the provided input.
Investor Verification Checklist
- Press Release Content: Retrieve and review Exhibit 99.1 (Press Release dated April 28, 2025) to understand the specific corporate event or announcement triggering this filing.
- Financial Impact: Verify if the announcement involves clinical trial results, partnership agreements, or regulatory updates that could impact future revenue or cash burn rates.
- Capital Position: Check the company's most recent 20-F or quarterly report for current cash reserves, as this 6-K does not update liquidity figures.